Lewis antigen test for pancreatic cancer prognosis
Part of Cancer clinical trials.
This study looks at how a special blood test (Lewis antigen) combined with a standard CA19-9 test might help predict the outlook for people with pancreatic cancer. You will give a small extra blood sample and have routine follow-up tests.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with pancreatic ductal adenocarcinoma (a type of pancreatic cancer).
- You are able to be up and about at least half the day (ECOG score 0-2).
- You do not have another type of cancer besides pancreatic cancer.
- You are willing to give a small blood sample (about 2-3 ml) for the Lewis antigen test and to have your CA19-9 levels checked regularly.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special blood test to look for tiny amounts of cancer DNA after your pancreatic cancer surgery. It may help doctors see early if the cancer is coming back, so they can act sooner.
This study is testing a new blood test to find pancreatic cancer early. It looks for tiny bits of cancer DNA floating in your blood, which could help catch the disease before symptoms start.
This study tests whether a blood test that looks at DNA changes (ctDNA methylation) can help predict how pancreatic cancer will behave and guide treatment decisions. It includes people with suspected pancreatic cancer who are planning surgery or a biopsy.
This study uses blood tests to look at how your immune system responds, to help find pancreatic cancer earlier. It compares people with pancreatic cancer, people with benign pancreatic conditions, and healthy people to improve diagnosis.
This trial studies whether a blood-based test can help detect pancreatic cancer (or strong signs of it) earlier than usual. The goal is to see how well “liquid biopsy” results match real diagnoses and risk levels.
This trial studies a blood test that looks for tiny traces of cancer-related DNA (called ctDNA) in people with pancreatic cancer that can be removed with surgery. The goal is to see whether this test can better predict how the cancer behaves and guide treatment decisions around surgery.
Hear when a new PDAC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.